Somatic mutations in IDH1 gene result in the production of a neomorphic enzyme that leads to the synthesis of the 2-Hydroxyglutarate (D-2HG) oncometabolite, instead of α-KG, thus altering numerous processes involved in epigenetics and cellular metabolism, and favoring tumor maintenance through immune evasion (34–37). This evidence concerns the gene IDH1 and neoplasm.